- Home
- LE vs CERS Comparison
LE vs CERS Comparison
Compare LE & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LE
- CERS
- Stock Information
- Founded
- LE 1963
- CERS 1991
- Country
- LE United States
- CERS United States
- Employees
- LE N/A
- CERS N/A
- Industry
- LE Clothing/Shoe/Accessory Stores
- CERS EDP Services
- Sector
- LE Consumer Discretionary
- CERS Technology
- Exchange
- LE Nasdaq
- CERS Nasdaq
- Market Cap
- LE 323.8M
- CERS 347.3M
- IPO Year
- LE N/A
- CERS 1997
- Fundamental
- Price
- LE $10.68
- CERS $1.40
- Analyst Decision
- LE Strong Buy
- CERS Strong Buy
- Analyst Count
- LE 2
- CERS 2
- Target Price
- LE $20.00
- CERS $3.50
- AVG Volume (30 Days)
- LE 146.6K
- CERS 1.5M
- Earning Date
- LE 03-20-2025
- CERS 05-01-2025
- Dividend Yield
- LE N/A
- CERS N/A
- EPS Growth
- LE N/A
- CERS N/A
- EPS
- LE 0.20
- CERS N/A
- Revenue
- LE $1,362,935,000.00
- CERS $180,270,000.00
- Revenue This Year
- LE $6.31
- CERS $25.22
- Revenue Next Year
- LE N/A
- CERS $10.08
- P/E Ratio
- LE $53.48
- CERS N/A
- Revenue Growth
- LE N/A
- CERS 15.29
- 52 Week Low
- LE $9.91
- CERS $1.34
- 52 Week High
- LE $19.88
- CERS $2.54
- Technical
- Relative Strength Index (RSI)
- LE 46.54
- CERS 38.37
- Support Level
- LE $9.97
- CERS $1.34
- Resistance Level
- LE $11.05
- CERS $1.58
- Average True Range (ATR)
- LE 0.58
- CERS 0.08
- MACD
- LE 0.01
- CERS -0.00
- Stochastic Oscillator
- LE 49.04
- CERS 24.00
About LE Lands' End Inc.
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically, it derives a majority of its revenue from the United States.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.